Immunogenicity and safety of the simultaneous administration of MR and yellow fever vaccines among Japanese adults

Immunogenicity and safety of the simultaneous administration of MR and yellow fever vaccines among Japanese adults - Immunogenicity and safety of the simultaneous administration of MR and yellow fever vaccines among Japanese adults

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000042738

Enrollment

Registered

2021-03-01

Start date

2021-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Yellow fever, Measles and Rubella

Interventions

Simultaneous administration of MR and yellow fever vaccines

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Japanese healthy adults need MR and yellow fever vaccines 2)20 years old and over and under 60 years old 3)No history of yellow fever 4)No history of immunization of yellow fever vaccine

Exclusion criteria

Exclusion criteria: 1)Manifest fever (37.5 or more temperature) 2)Suffering from severe acute illness 3)History of anaphylaxis 4)Immunodeficiency 5)HIV infection 6)Immunosuppressive and Immunomodulatory Therapies 7)Neurological disorder 8)Thymus Disorder 9)History of hypersensitivity to MR and yellow fever vaccine 10)Other chronic medical conditions 11)Pregnancy 12)Brestfeeding 13)Other inappropriate condition for vaccination

Design outcomes

Primary

Measure	Time frame
Immunogenicity 1)Seroprotection to yellow fever after the simultaneous administration with yelloe fever and MR vaccines	—

Secondary

Measure	Time frame
Safety 1)Adverse events wihin 28 days after the simultaneous administration with yelloe fever and MR vaccines Immunogenicity 2)Geometric mean titer(GMT) of yellow fever virus titer 4-6 weeks after the simultaneous administration with yelloe fever and MR vaccine 3)Seroconversion and GMTs of measles or rubella virus titers 4-6 weeks after the simultaneous administration with yelloe fever and MR vaccines	—

Measure

Time frame

Safety 1)Adverse events wihin 28 days after the simultaneous administration with yelloe fever and MR vaccines Immunogenicity 2)Geometric mean titer(GMT) of yellow fever virus titer 4-6 weeks after the simultaneous administration with yelloe fever and MR vaccine 3)Seroconversion and GMTs of measles or rubella virus titers 4-6 weeks after the simultaneous administration with yelloe fever and MR vaccines

—

Countries

Japan

Contacts

Public ContactSHINJI FUKUSHIMA

Tokyo Medical University Hospital Travellers' Medical Center

fuku789@tokyo-med.ac.jp0333426111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026